{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:17:04Z","timestamp":1793902624094,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs) show minimal efficacy in recurrent high-grade astrocytoma (rHGA). Laser interstitial thermal therapy (LITT), a minimally invasive cytoreductive approach, may prime rHGA for ICI response. A phase 1\/randomized phase 2b trial (ClinicalTrials.gov:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT02311582?term=NCT02311582&amp;rank=1\" ext-link-type=\"uri\">NCT02311582<\/jats:ext-link>\n                    ) was designed to test pembrolizumab in combination with LITT in patients with rHGA. Nine patients were enrolled in the phase I dose-escalation lead-in study. No dose-limiting toxicities were observed and 200\u2009mg of pembrolizumab every three weeks was determined as the recommended phase 2 dose. The phase 2b study was initially designed to randomize (up to 45) patients 1:1 to either LITT followed by pembrolizumab (LITT\u2009+\u2009PEM) or non-LITT surgery followed by pembrolizumab (NLS\u2009+\u2009PEM). Phase 2\u2019s primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), safety, and immune signature. After 21 patients, based on an independent Data and Safety Monitoring Committee request of unscheduled interim review of accumulating efficacy data, randomization stopped as benefit from NLS\u2009+\u2009PEM appeared limited, and the subsequent 24 patients received LITT\u2009+\u2009PEM. The pre-specified study endpoints were achieved. Among 39 per-protocol patients, LITT\u2009+\u2009PEM (n\u2009=\u200933) improved median OS (11.8 versus 5.2 months) and 18-month survival (42% versus 0%) compared to NLS\u2009+\u2009PEM (n\u2009=\u20096) (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06\u20130.49; P\u2009=\u20090.0002). Median PFS was longer in LITT\u2009+\u2009PEM (4.5 versus 1.6 months; HR 0.21; 95% CI, 0.08\u20130.56; P\u2009=\u20090.0006). In an intent-to-treat sensitivity analysis (n\u2009=\u200921), OS (HR 0.29; 95% CI, 0.10\u20130.88) and PFS (HR 0.30; 95% CI, 0.10\u20130.87) again favored LITT\u2009+\u2009PEM (n\u2009=\u200913). Treatment was well tolerated. LITT activated non-classical monocytes, and pembrolizumab unleashed CD8\u207a T cell proliferation, clonal expansion, and coordinated memory T-cell responses. Overall,\u00a0LITT\u2009+\u2009PEM is safe and may overcome rHGA immunosuppression to generate antitumor immunity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-69522-w","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:02:58Z","timestamp":1772100178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1\/randomized Phase 2b trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Jian L.","family":"Campian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Son B.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-4610","authenticated-orcid":false,"given":"Ashley","family":"Ghiaseddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar H.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshit","family":"Manektalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-3898","authenticated-orcid":false,"given":"Dongjiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-7907","authenticated-orcid":false,"given":"Jingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Leidig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Johanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7178-8777","authenticated-orcid":false,"given":"George","family":"Ansstas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-5232","authenticated-orcid":false,"given":"Sangami","family":"Pugazenthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-506X","authenticated-orcid":false,"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8282-9098","authenticated-orcid":false,"given":"Milan G.","family":"Chheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-8493","authenticated-orcid":false,"given":"Albert H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4154-3135","authenticated-orcid":false,"given":"Eric C.","family":"Leuthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-8921","authenticated-orcid":false,"given":"David D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"69522_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170\u2013186 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69522_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41577-021-00617-9","volume":"21","author":"JD Wolchok","year":"2021","unstructured":"Wolchok, J. D. Checkpoint blockade: the end of the beginning. Nat. Rev. Immunol. 21, 621\u2013621 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"69522_CR3","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/cncr.33378","volume":"127","author":"DA Reardon","year":"2021","unstructured":"Reardon, D. A. et al. Treatment with pembrolizumab in programmed death ligand 1\u2013positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127, 1620\u20131629 (2021).","journal-title":"Cancer"},{"key":"69522_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma. JAMA Oncol. 6, 1003 (2020).","journal-title":"JAMA Oncol."},{"key":"69522_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","volume":"27","author":"L Nayak","year":"2021","unstructured":"Nayak, L. et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin. Cancer Res. 27, 1048\u20131057 (2021).","journal-title":"Clin. Cancer Res."},{"key":"69522_CR6","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"69522_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro Oncol."},{"key":"69522_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14791\/btrt.2022.10.e25","volume":"10","author":"M-H Han","year":"2022","unstructured":"Han, M.-H. & Kim, C. H. Current immunotherapeutic approaches for malignant gliomas. Brain Tumor Res. Treat. 10, 1 (2022).","journal-title":"Brain Tumor Res. Treat."},{"key":"69522_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 470\u2013476 (2019).","journal-title":"Nat. Med."},{"key":"69522_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25, 462\u2013469 (2019).","journal-title":"Nat. Med."},{"key":"69522_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"69522_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa, J. R. et al. Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat. Commun. 15, 10757 (2024).","journal-title":"Nat. Commun."},{"key":"69522_CR13","first-page":"7462","volume":"63","author":"S Wintterle","year":"2003","unstructured":"Wintterle, S. et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63, 7462\u20137467 (2003).","journal-title":"Cancer Res."},{"key":"69522_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/00001756-200507130-00010","volume":"16","author":"R Wilmotte","year":"2005","unstructured":"Wilmotte, R. et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16, 1081\u20131085 (2005).","journal-title":"Neuroreport"},{"key":"69522_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84\u201388 (2007).","journal-title":"Nat. Med."},{"key":"69522_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1215\/15228517-2009-014","volume":"11","author":"Y Yao","year":"2009","unstructured":"Yao, Y. et al. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro. Oncol. 11, 757\u2013766 (2009).","journal-title":"Neuro. Oncol."},{"key":"69522_CR17","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1158\/1078-0432.CCR-12-3314","volume":"19","author":"O Bloch","year":"2013","unstructured":"Bloch, O. et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res. 19, 3165\u20133175 (2013).","journal-title":"Clin. Cancer Res."},{"key":"69522_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000362817","volume":"87","author":"G Rahmathulla","year":"2014","unstructured":"Rahmathulla, G. et al. MRI-guided laser interstitial thermal therapy in neuro-oncology: a review of its current clinical applications. Oncology 87, 67\u201382 (2014).","journal-title":"Oncology"},{"key":"69522_CR19","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2016.7.FOCUS16234","volume":"41","author":"JG Thomas","year":"2016","unstructured":"Thomas, J. G., Rao, G., Kew, Y. & Prabhu, S. S. Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma. Neurosurg. Focus 41, E12 (2016).","journal-title":"Neurosurg. Focus"},{"key":"69522_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/02656736.2020.1783461","volume":"37","author":"B Patel","year":"2020","unstructured":"Patel, B., Yang, P. H. & Kim, A. H. The effect of thermal therapy on the blood-brain barrier and blood-tumor barrier. Int. J. Hyperth. 37, 35\u201343 (2020).","journal-title":"Int. J. Hyperth."},{"key":"69522_CR21","doi-asserted-by":"publisher","first-page":"e0148613","DOI":"10.1371\/journal.pone.0148613","volume":"11","author":"EC Leuthardt","year":"2016","unstructured":"Leuthardt, E. C. et al. Hyperthermic laser ablation of recurrent glioblastoma leads to temporary disruption of the peritumoral blood brain barrier. PLoS ONE 11, e0148613 (2016).","journal-title":"PLoS ONE"},{"key":"69522_CR22","doi-asserted-by":"crossref","unstructured":"Pandey A et al. Safety and efficacy of laser interstitial thermal therapy as upfront therapy in primary glioblastoma and IDH-mutant astrocytoma: a meta-analysis. Cancers 16, 2131 (2024).","DOI":"10.3390\/cancers16112131"},{"key":"69522_CR23","first-page":"vdac040","volume":"4","author":"JF de Groot","year":"2022","unstructured":"de Groot, J. F. et al. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neurooncol. Adv. 4, vdac040 (2022).","journal-title":"Neurooncol. Adv."},{"key":"69522_CR24","doi-asserted-by":"crossref","unstructured":"Salehi A et al. Therapeutic enhancement of blood\u2013brain and blood\u2013tumor barriers permeability by laser interstitial thermal therapy. Neurooncol. Adv. 2, vdaa071 (2020).","DOI":"10.1093\/noajnl\/vdaa071"},{"key":"69522_CR25","doi-asserted-by":"crossref","unstructured":"Butt OH et al. A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neurooncol. Adv. 3, vdab164 (2021).","DOI":"10.1093\/noajnl\/vdab164"},{"key":"69522_CR26","unstructured":"National Comprehensive Cancer Network. Central Nervous System Cancers Cancer (Version 4.2024). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1425. Accessed March 1, 2025)."},{"key":"69522_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11060-020-03557-x","volume":"151","author":"DH Shin","year":"2021","unstructured":"Shin, D. H., Melnick, K. F., Tran, D. D. & Ghiaseddin, A. P. In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas. J. Neurooncol. 151, 85\u201392 (2021).","journal-title":"J. Neurooncol."},{"key":"69522_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/CJI.0000000000000485","volume":"46","author":"JS Chandar","year":"2023","unstructured":"Chandar, J. S. et al. Laser interstitial thermal therapy induces robust local immune response for newly diagnosed glioblastoma with long-term survival and disease control. J. Immunother. 46, 351\u2013354 (2023).","journal-title":"J. Immunother."},{"key":"69522_CR29","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."},{"key":"69522_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100708","volume":"6","author":"D Chen","year":"2025","unstructured":"Chen, D. et al. Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: a phase 2 study. Med 6, 100708 (2025).","journal-title":"Med"},{"key":"69522_CR31","doi-asserted-by":"crossref","unstructured":"Chen D et al. Tumor treating fields dually activate Sting and Aim2 inflammasomes to induce adjuvant immunity in glioblastoma. J. Clin. Investig. 132, e149258 (2022).","DOI":"10.1172\/JCI149258"},{"key":"69522_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","volume":"11","author":"EA Chiocca","year":"2019","unstructured":"Chiocca, E. A. et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).","journal-title":"Sci. Transl. Med."},{"key":"69522_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"69522_CR34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"69522_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2019","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","journal-title":"Nat. Biotechnol."},{"key":"69522_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13073-015-0169-8","volume":"7","author":"V Greiff","year":"2015","unstructured":"Greiff, V. et al. A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status. Genome Med. 7, 49\u201349 (2015).","journal-title":"Genome Med."},{"key":"69522_CR37","first-page":"47","volume":"5","author":"LN Vaserstein","year":"1969","unstructured":"Vaserstein, L. N. Markov processes on a countable product of spaces that describe large systems of automata. Probl. Inf. Transm. 5, 47\u201352 (1969).","journal-title":"Probl. Inf. Transm."},{"key":"69522_CR38","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1093\/bioinformatics\/btab226","volume":"37","author":"R Schefzik","year":"2021","unstructured":"Schefzik, R., Flesch, J. & Goncalves, A. Fast identification of differential distributions in single-cell RNA-sequencing data with waddR. Bioinformatics 37, 3204\u20133211 (2021).","journal-title":"Bioinformatics"},{"key":"69522_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41577-024-01078-6","volume":"24","author":"K Minton","year":"2024","unstructured":"Minton, K. Non-classical monocytes have the support of the whole vascular tree. Nat. Rev. Immunol. 24, 619\u2013619 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"69522_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00477-1","volume":"7","author":"CE Olingy","year":"2017","unstructured":"Olingy, C. E. et al. Non-classical monocytes are biased progenitors of wound healing macrophages during soft tissue injury. Sci. Rep. 7, 447 (2017).","journal-title":"Sci. Rep."},{"key":"69522_CR41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41577-020-0307-4","volume":"20","author":"NM Adams","year":"2020","unstructured":"Adams, N. M., Grassmann, S. & Sun, J. C. Clonal expansion of innate and adaptive lymphocytes. Nat. Rev. Immunol. 20, 694\u2013707 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"69522_CR42","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","volume":"6","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal, C. et al. Assessment of Tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open 6, e2311181\u2013e2311181 (2023).","journal-title":"JAMA Netw. Open"},{"key":"69522_CR43","doi-asserted-by":"crossref","unstructured":"\u015aledzi\u0144ska, P., Bebyn, MG., Furtak, J., Kowalewski, J. & Lewandowska, MA. Prognostic and Predictive biomarkers in gliomas. Int. J. Mol. Sci. 22, 10373 (2021).","DOI":"10.3390\/ijms221910373"},{"key":"69522_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang, R. & Zhou, P.-K. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct. Target. Ther. 6, 254 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"69522_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes, M. N. & Lewin, S. R. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91\u2013104 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"69522_CR46","doi-asserted-by":"crossref","unstructured":"Zhai, L. et al. Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies. Front. Immunol. 11, 1185 (2020).","DOI":"10.3389\/fimmu.2020.01185"},{"key":"69522_CR47","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083\u20131097 (2019).","journal-title":"Lancet Oncol."},{"key":"69522_CR48","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"69522_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","volume":"5","author":"S Lu","year":"2019","unstructured":"Lu, S. et al. Comparison of biomarker modalities for predicting response to pd-1\/pd-l1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 5, 1195\u20131204 (2019).","journal-title":"JAMA Oncol."},{"key":"69522_CR50","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.bjc.6602105","volume":"91","author":"E Franceschi","year":"2004","unstructured":"Franceschi, E. et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br. J. Cancer 91, 1038\u20131044 (2004).","journal-title":"Br. J. Cancer"},{"key":"69522_CR51","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/cncr.21316","volume":"104","author":"DA Reardon","year":"2005","unstructured":"Reardon, D. A. et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104, 1478\u20131486 (2005).","journal-title":"Cancer"},{"key":"69522_CR52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1212\/01.WNL.0000140495.33615.CA","volume":"63","author":"AA Brandes","year":"2004","unstructured":"Brandes, A. A. et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63, 1281\u20131284 (2004).","journal-title":"Neurology"},{"key":"69522_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1212\/WNL.56.1.118","volume":"56","author":"AC Kappelle","year":"2001","unstructured":"Kappelle, A. C. et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56, 118\u2013120 (2001).","journal-title":"Neurology"},{"key":"69522_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1215\/S1152851703000188","volume":"6","author":"SL Chua","year":"2004","unstructured":"Chua, S. L. et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol. 6, 38\u201343 (2004).","journal-title":"Neuro Oncol."},{"key":"69522_CR55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289\u2013307.e289 (2020).","journal-title":"Cancer Cell"},{"key":"69522_CR56","doi-asserted-by":"crossref","unstructured":"Abeysekera, W. & Sooriyarachchi, M. Use of Schoenfeld\u2019s global test to test the proportional hazards assumption in the Cox proportional hazards model: an application to a clinical study. J. Natl. Sci. Found. Sri Lanka 37, 41\u201345 (2009).","DOI":"10.4038\/jnsfsr.v37i1.456"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69522-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69522-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69522-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:03:02Z","timestamp":1772100182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69522-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69522"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69522-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D.T. has research funding from Merck, is a consultant for and received research funding from Monteris Medical, serves as a consultant for Novocure, and has research funding from Novocure, TVax, Novartis, Lacerta Therapeutics, Sarepta, Stemline, and Northwest Biotech for other unrelated work. A.P.G. has received personal honoraria for consultant work from Monteris Medical, Alexion Pharmaceuticals, Servier, ONO Pharma USA, Neosoma, Aptitude Health, Guidepoint, and Novocure. A.P.G. has held personal stock in Viatris Inc. O.H.B. serves on the advisory board for Novocure and as a consultant for Menarini. A.H.K. is a consultant for Monteris Medical and has research funding from Stryker to study a dural substitute, which has no direct relation to this study. J.L.C. received research fundings to support investigator-initiated studies from Merck, Incyte and GI Innovation, which have no direct relation to this study. E.C.L. owns stock in Neurolutions, Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Aurenar, Petal Surgical, Cordance Medical, and Silent Surgical. He serves as a consultant for Monteris Medical, E15, and Neurolutions. He receives licensing fees from Neurolutions and Sora Neuroscience. Additionally, Washington University owns equity in Neurolutions. M.G.C. receives royalties from UpToDate. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1763"}}